Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Next Previous
Trial Profile

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Alzheimer's disease; Corticobasal degeneration; Dementia; Lewy body disease; Neurodegenerative disorders; Parkinson's disease; Progressive supranuclear palsy; Vascular dementia
  • Focus Adverse reactions; Registrational
  • Sponsors Acadia Pharmaceuticals

Most Recent Events

  • 08 May 2024 According to an Acadia Pharmaceuticals media release, favorable results from a Phase 3b trial evaluating the safety and tolerability of NUPLAZID (pimavanserin) in patients with neuropsychiatric symptoms related to neurodegenerative diseases 60 years of age and older published in he Journal of Alzheimers Disease.
  • 20 Jul 2023 Results assessing safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms presented at the Alzheimer's Association International Conference 2023
  • 06 Jun 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top